Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GM-CSF for Sepsis Immunoparalysis
NCT00252915Phase 2Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Nov 2005
- Primary completion
- Jan 2007
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, double-blind trial in sepsis and septic shock comparing GM-CSF with Placebo (2 arms). Primary endpoint: Reconstitution of monocytic immunity (mHLA-DR expression) at Day 9. Started Nov 2005; status: completed.
02
Drugs
sargramostim
03
Conditions
sepsisseptic shock
Beyond the preview
Go deeper on NCT00252915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00252915.